- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc stock price live, this page displays NASDAQ XENE stock exchange data. View the XENE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xenon Pharmaceuticals Inc real time stock price chart below.
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 58.88.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock ticker symbol for Xenon Pharmaceuticals Inc is XENE.
Is XENE the Same as $XENE?
$XENE is a common way to refer to the Xenon Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Xenon Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 58.88.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock ticker symbol for Xenon Pharmaceuticals Inc is XENE.
Is XENE the Same as $XENE?
$XENE is a common way to refer to the Xenon Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Xenon Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
58.35
59.70
52 wk Range
28.19
63.95
XENE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
58.3559.70
52 wk Range
28.1963.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XENE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
79.24
Upside
+34.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc SWOT Analysis
Financial Outlook | With a strong balance sheet and analyst price targets ranging from $42 to $65, Xenon navigates market volatility amid clinical progress and setbacks |
Diverse Pipeline | Explore Xenon's robust drug portfolio beyond azetukalner, including promising candidates for various neurological disorders and innovative research initiatives |
Market Potential | Analysts project blockbuster status for azetukalner, with peak sales potentially exceeding $1 billion annually in epilepsy and depression markets |
Pivotal Trials Ahead | Xenon Pharmaceuticals approaches critical phase with lead drug azetukalner in focal onset seizures and major depressive disorder trials, despite recent delays |
Xenon Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Xenon Pharmaceuticals reported Q3 2025 EPS of -$1.15, meeting analyst expectations, while stock declined 1.91% to $41.92, with an additional 1.6% drop after hours.
- Cash reserves decreased from $754.4M to $555.3M, but remain sufficient to fund operations into 2027, supporting late-stage clinical developments.
- The company has exceeded patient randomization targets for Ezetikelner's Phase 3 epilepsy study, with top-line data and potential NDA submission expected in 2026.
- Xenon appointed a new CFO to strengthen commercialization efforts as it pursues its long-term goal of becoming a fully integrated neuroscience-focused biopharma company.
- Management expressed high confidence in the XTOL-2 study outcomes while acknowledging risks including clinical trial results, market competition, and regulatory hurdles.
Last Updated: 11/03/2025, 06:12 PM
Read Full TranscriptCompare XENE to Peers and Sector
Metrics to compare | XENE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXENEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.2x | −4.3x | −0.5x | |
PEG Ratio | 0.36 | −0.29 | 0.00 | |
Price / Book | 9.7x | 5.9x | 2.6x | |
Price / LTM Sales | 749.2x | 10.8x | 3.2x | |
Upside (Analyst Target) | 34.8% | 92.5% | 45.7% | |
Fair Value Upside | Unlock | 6.1% | 4.8% | Unlock |
Analyst Ratings
20 Buy
0 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 79.24
(+34.58% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-1.31 / -1.19
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Xenon Pharmaceuticals (XENE) Stock Price Today?
The Xenon Pharmaceuticals stock price today is 58.88 USD.
What Stock Exchange Does Xenon Pharmaceuticals Trade On?
Xenon Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Xenon Pharmaceuticals?
The stock symbol for Xenon Pharmaceuticals is "XENE."
What Is the Xenon Pharmaceuticals Market Cap?
As of today, Xenon Pharmaceuticals market cap is 5.62B USD.
What Is Xenon Pharmaceuticals's Earnings Per Share (TTM)?
The Xenon Pharmaceuticals EPS (TTM) is -4.36.
When Is the Next Xenon Pharmaceuticals Earnings Date?
Xenon Pharmaceuticals will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is XENE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Xenon Pharmaceuticals Stock Split?
Xenon Pharmaceuticals has split 0 times.
How Many Employees Does Xenon Pharmaceuticals Have?
Xenon Pharmaceuticals has 364 employees.
What is the current trading status of Xenon Pharmaceuticals (XENE)?
As of Apr 16, 2026, Xenon Pharmaceuticals (XENE) is trading at a price of 58.88 USD, with a previous close of 59.35 USD. The stock has fluctuated within a day range of 58.35 USD to 59.70 USD, while its 52-week range spans from 28.19 USD to 63.95 USD.
What Is Xenon Pharmaceuticals (XENE) Price Target According to Analysts?
The average 12-month price target for Xenon Pharmaceuticals is 79.24 USD, with a high estimate of 100 USD and a low estimate of 58.58 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +34.58% Upside potential.
What Is the XENE Premarket Price?
XENE's last pre-market stock price is 59.33 USD. The pre-market share volume is 530.00, and the stock has decreased by -0.02, or -0.03%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.